EZH2 is a druggable target in different cancers [6], and commercial catalytic EZH2i, such as EPZ005687 and GSK2816126 (Figure 2A), are used in lymphoma with EZH2-activating mutations and also in solid tumors [20, 21, 26]. Here, EZH2 is linked to lymphoma.